Jabbit

Home › Research › Lilly’s retatrutide lawsuits

Evidence teardown · Retatrutide · Courts and regulation · Updated October 27, 2026

Published · Updated

Who is Eli Lilly suing over retatrutide, and what does it mean if you bought “reta” online? Lilly has filed 11 federal lawsuits against online sellers, med spas, a clinic and a compounding pharmacy. Three ended with prejudice, eight are open, no court has ruled on the merits, and no buyer has been sued

Retatrutide is Eli Lilly’s experimental weekly shot for obesity. It is still in trials and, in Lilly’s words, “No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world.”[3] That has not stopped vials labeled “reta” from being sold online and through clinics. The reader’s question: who is Lilly suing, how are the cases going, and should buyers worry? Our plain answer: Lilly has sued 11 sellers and clinics. Three cases ended with prejudice, eight are open, and no court has decided whether Lilly’s claims are right. The suits target sellers, not people who bought the product. The bigger risk for buyers is not legal but medical: nobody can verify what is in an unapproved vial.[1][17][18]

Why this matters now

On October 26, 2026, Bloomberg Law reported that Lilly “has filed at least 11 federal lawsuits against a range of online vendors and wellness clinics” over copycat retatrutide.[1] In the two weeks before that, Lilly dropped two of the cases with prejudice, a court set a November 30 conference in the case where a seller is fighting back, and a compounding pharmacy’s response came due October 30.[9][10][6][8] Meanwhile, poison center reports involving retatrutide have kept rising through 2026.[19]

Timeline

Date (2026)Event
June 19Victoria, Australia, warns of six liver injury cases in people who used products labeled retatrutide, “possibly associated with a contaminant.”[18]
Aug 12Lilly announces six lawsuits against U.S. sellers and says it has referred more than 200 people and companies to FDA.[3]
Aug 31Lilly amends the Astra complaint to add a seller whose real identity it says it does not know.[5]
Sept 11Lilly drops the Aesthetic Envy case with prejudice.[4]
Oct 1FDA says retatrutide cannot be used in compounding and lists warnings to telehealth companies, ingredient distributors and outsourcing facilities.[17]
Oct 2Legendary Peptides asks the court to dismiss Lilly’s suit.[7]
Oct 8Lilly files five more suits, including against a med spa and a weight-loss clinic.[2]
Oct 13CBS News reports two deaths reported to FDA after use of products claiming to be retatrutide; the reports are unverified.[19]
Oct 15–16Lilly drops the Texas Peptides and Lone Star Peptide cases with prejudice.[9][10]
Oct 26Bloomberg Law counts at least 11 suits.[1]
Oct 30Striker Pharmacy’s response to the complaint is due.[8]
Nov 30Case management conference in the Legendary Peptides case.[6]

All 11 cases at a glance

Timeline of Eli Lilly’s 11 retatrutide lawsuits from filing to October 27, 2026: Aesthetic Envy (E.D. Cal.) dropped with prejudice Sept 11; Texas Peptides (W.D. Tex.) dropped with prejudice Oct 15; Lone Star Peptide (S.D. Tex.) dropped with prejudice Oct 16; Astra (W.D. Tex.), Legendary Peptides (E.D. Tex., conference Nov 30), Striker Pharmacy (S.D. Tex., response due Oct 30), American Peptides (W.D. La.), an individual seller (N.D. Tex.), Cenexa Labs (S.D. Tex.), Southlake Mhya (Medrein, N.D. Tex.) and MedShape Weight Loss Clinic (D. Ariz.) still open.
Built by Jabbit from the CourtListener dockets and filings in references 4–15. “Dropped with prejudice” means Lilly filed a notice ending the case for good; the notices state no terms.
Defendant (as named in court)Type, per LillyCourt and caseFiledStatus on Oct 27
Aesthetic Envy Cosmetic CentersMed spaE.D. Cal. 2:26-cv-02764Aug 12Dropped with prejudice Sept 11[4]
Astra LLC, plus an unidentified seller added Aug 31Online “research use” sellerW.D. Tex. 5:26-cv-05147Aug 12Open; Lilly is asking for discovery to identify the seller[5]
Legendary PeptidesOnline sellerE.D. Tex. 1:26-cv-00347Aug 12Open; motion to dismiss pending; conference Nov 30[6]
Striker PharmacyCompounding pharmacyS.D. Tex. 4:26-cv-06563Aug 12Open; response due Oct 30[8]
Texas PeptidesOnline sellerW.D. Tex. 5:26-cv-05146Aug 12Dropped with prejudice Oct 15[9]
Lone Star Peptide Co.Online sellerS.D. Tex. 4:26-cv-06562Aug 12Dropped with prejudice Oct 16[10]
American PeptidesOnline sellerW.D. La. 5:26-cv-04146Oct 8Open; summons issued Oct 16[11]
Owner of LiveWell Peptides (individual)Online sellerN.D. Tex. 3:26-cv-03514Oct 8Open[12]
Cenexa LabsOnline sellerS.D. Tex. 4:26-cv-08806Oct 8Open[13]
Southlake Mhya (Medrein Health & Aesthetics)Med spaN.D. Tex. 4:26-cv-01294Oct 8Open[14]
MedShape Weight Loss ClinicWeight-loss clinicD. Ariz. 2:26-cv-07361Oct 8Open; served Oct 15[15]

Defendant types are how Lilly describes them in its filings or release. The complaints contain Lilly’s allegations; none has been proven in court.[3][8][14]

What Lilly is claiming

Lilly does not hold an approved retatrutide product to protect, so the suits rest on unfair competition and false advertising claims, not on drug approval itself. The seller and pharmacy cases rely on state unfair-competition and consumer-protection laws. The Striker Pharmacy and American Peptides complaints each plead eight causes of action, under seven states’ statutes and Texas common law.[8][11] The med spa and clinic cases filed in October add federal false advertising claims under the Lanham Act. In them, Lilly alleges the businesses compared their products to approved weight-loss drugs and leaned on Lilly’s own trial data, and asks for court-ordered corrective advertising.[14][15]

The complaints repeat one line: “Retatrutide cannot legally be sold for human use to anyone, anywhere, for any reason.”[8] In the Striker case, Lilly alleges that a Texas compounding pharmacy sold the products to med spas and shipped them directly to consumers.[8] FDA has separately said retatrutide “cannot be used in compounding under federal law.”[17]

The other side: a seller fights back

Only one defendant has filed a full response so far. Legendary Peptides’ motion to dismiss argues that Lilly lacks standing because “Lilly does not sell retatrutide, and on its own allegations it cannot.” It sums up: “That is the whole case: Lilly seeks damages for lost sales due to a product it does not and cannot lawfully sell.”[7] It also argues that Texas law does not allow an unfair-competition claim built on a state drug-law violation, “as two courts have already held in Lilly’s own cases.”[7] The court has not ruled. It gave Lilly 44 days from service of the motion to respond and set a case management conference for November 30.[6]

Jabbit analysis: this standing question is the legal crux. If courts accept it, Lilly’s private suits may do less than its public referrals to regulators. If courts reject it, the October Lanham Act cases against clinics could become the template.

Why three cases ended

Lilly ended the Aesthetic Envy, Texas Peptides and Lone Star Peptide cases by filing notices of voluntary dismissal with prejudice.[4][9][10] Under federal rules, a plaintiff can do that without a court order before the defendant answers. “With prejudice” means the claims cannot be refiled.[16] The notices themselves give no reason and no terms, so the court record does not say whether there was a settlement.[9][10] In Astra, Lilly filed a dismissal notice on September 2 but then asked the court to let it take discovery to identify the seller, and the docket remains open.[5]

What this means if you bought “reta”

Bar chart of retatrutide exposures logged by U.S. poison centers in 2026: 249 in the first quarter, 460 in the second and 862 in the third, as reported by CBS News.
An exposure is a report to a poison center, not proof of harm. Figures from CBS News, citing America’s Poison Centers.[19]

If you have used a product sold as retatrutide and feel unwell, especially with yellowing skin or eyes, dark urine, severe belly pain or vomiting, contact a doctor or poison control (1-800-222-1222 in the U.S.). Tell them exactly what you took. For what the trials of the real drug show, see our retatrutide trial summary.

What a careful reader should notice

  1. “11 lawsuits” is a filing count, not a scorecard. No court has found any defendant liable.[1][20]
  2. The three ended cases were closed by Lilly’s own notices, which state no terms.[4][9][10]
  3. The strongest public argument against the suits comes from a defendant, so it is advocacy, not a ruling.[7]
  4. Lilly’s release has at least one detail that differs from the court record: it lists the Aesthetic Envy case in the Northern District of California, while the filings are in the Eastern District.[3][4]
  5. The safety signals, from Victoria’s liver cases, death reports and poison center counts, are real but uncontrolled. None proves what was in a given vial.[18][19]

FAQ

Who has Eli Lilly sued over retatrutide?
Eleven defendants in federal courts in Texas, California, Louisiana and Arizona. Six were sued on August 12, 2026, including online sellers, a compounding pharmacy and a med spa. Five more were sued on October 8, including a med spa and a weight-loss clinic. The table above lists each by court and case number.
Is it illegal to buy retatrutide online?
Lilly’s lawsuits target sellers, not buyers, and we found no case against a buyer. Retatrutide is not approved anywhere, and FDA says it cannot be used in compounding. Anything sold as retatrutide is an unapproved product of unverified content, whatever the label says.
Did Lilly win any of the lawsuits?
Not on the merits. Lilly dropped three cases with prejudice in September and October 2026, and the notices state no terms. Eight cases are open, and no court has ruled on whether Lilly’s claims are valid.
What happens next in the retatrutide cases?
Striker Pharmacy’s response to Lilly’s complaint is due October 30, 2026. In the Legendary Peptides case, Lilly must respond to a pending motion to dismiss, and a case management conference is set for November 30. In the Striker case, discovery runs to August 10, 2027.
Are “research use only” peptides legal to sell?
Lilly alleges that some sellers use a “research use only” label on products that are really meant for people. That is Lilly’s allegation, and courts have not decided it in these cases. FDA has warned companies for marketing unapproved retatrutide directly to consumers.
Is black-market retatrutide dangerous?
It can be. Victoria, Australia, reported six liver injury cases possibly linked to a contaminant in products labeled retatrutide. CBS News found two unverified death reports to FDA, and U.S. poison center exposures reached 862 in the third quarter of 2026. If you feel unwell after using it, see a doctor.

Bottom line

Lilly’s 11 lawsuits are a legal campaign against sellers and clinics, not a verdict. Three cases are closed on Lilly’s own notices, eight are open, and the main defense argument, that Lilly cannot claim lost sales on a drug it cannot sell, is still before a judge. For anyone who bought “reta,” the court fight matters less than the fact that no regulator has approved the drug and no buyer can verify what is in the vial.

References

  1. Bloomberg Law, Nyah Phengsitthy, “Eli Lilly Toughens Legal Game Plan Over Next Weight Loss Drug,” October 26, 2026, 5:05 AM ET (paywalled; free lede read): Lilly “has filed at least 11 federal lawsuits against a range of online vendors and wellness clinics making copycat versions of its experimental drug retatrutide, accusing them of illegally selling or facilitating access to a product not approved by any regulator in the world.” https://news.bloomberglaw.com/health-law-and-business/eli-lilly-toughens-legal-game-plan-over-next-weight-loss-drug. Checked October 27, 2026.
  2. Bloomberg Law, “Eli Lilly Sues More Vendors Selling ‘Illicit’ Weight Loss Drugs,” October 8, 2026 (free lede read): “The lawsuits target American Peptides LLC, LiveWell Peptides, Cenexa Labs LLC, Medrein Health & Aesthetics, and Medshape Weight Loss Clinic LLC.” https://news.bloomberglaw.com/health-law-and-business/eli-lilly-sues-more-vendors-selling-illicit-weight-loss-drugs. Checked October 27, 2026.
  3. Eli Lilly and Company press release, “Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market,” August 12, 2026 (PR Newswire copy; Lilly’s investor site blocked automated reading). Lilly says it is “filing six new lawsuits against U.S. entities selling black-market products”; that the suits target “compounding pharmacies, medical spas, and online sellers that falsely claim their drugs are for “research-use only” when they are actually intended for human use”; that it “referred more than 200 individuals and entities to FDA”; and that it “reported more than 14,000 websites, advertisements, social media posts and product listings that unlawfully market retatrutide in over 100 countries.” Lilly chief medical officer David A. Hyman, M.D., is quoted: “What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk.” Also: “No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world.” The release lists the Aesthetic Envy case as N.D. Cal.; the court filings show E.D. Cal. https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html. Checked October 27, 2026.
  4. Eli Lilly and Co. v. Aesthetic Envy Cosmetic Centers LLC, No. 2:26-cv-02764 (E.D. Cal., filed Aug 12, 2026). Docket: https://www.courtlistener.com/docket/74642491/. Notice of voluntary dismissal with prejudice, dated September 11, 2026 (ECF 6): https://storage.courtlistener.com/recap/gov.uscourts.caed.497764/gov.uscourts.caed.497764.6.0.pdf. Checked October 27, 2026.
  5. Eli Lilly and Company v. Astra LLC, No. 5:26-cv-05147 (W.D. Tex., filed Aug 12, 2026). Docket: https://www.courtlistener.com/docket/74538839/. First amended complaint, August 31, 2026 (ECF 6), adding an operator “whose true legal identity is presently unknown” and describing the defendants as claiming “to be an online seller of purportedly “research use only” products”: https://storage.courtlistener.com/recap/gov.uscourts.txwd.1172926918/gov.uscourts.txwd.1172926918.6.0.pdf. Docket entries: Lilly notice of voluntary dismissal, September 2, 2026 (ECF 7; document not public); “MOTION To Allow Pre-Service Discovery to Determine Defendant’s Identity,” September 30, 2026 (ECF 8). Case open when checked. Checked October 27, 2026.
  6. Eli Lilly and Company v. Legendary Peptides, LLC, No. 1:26-cv-00347 (E.D. Tex., filed Aug 12, 2026). Docket: https://www.courtlistener.com/docket/74513889/. Order: Lilly “shall file any response to that motion withing 44 days after the motion is served” (sic, docket text). Amended order, October 19, 2026 (ECF 19): “Rule 16 Case Management Conference” set for November 30, 2026: https://storage.courtlistener.com/recap/gov.uscourts.txed.248221/gov.uscourts.txed.248221.19.0.pdf. Checked October 27, 2026.
  7. Legendary Peptides, LLC, Motion to Dismiss Complaint Under Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6), No. 1:26-cv-00347 (E.D. Tex.), filed October 2, 2026 (ECF 12). Quotes: “Lilly does not sell retatrutide, and on its own allegations it cannot.” “That is the whole case: Lilly seeks damages for lost sales due to a product it does not and cannot lawfully sell.” “Texas does not recognize a common-law unfair-competition claim built on a violation of the Texas Food, Drug, and Cosmetic Act, as two courts have already held in Lilly’s own cases.” These are the defendant’s arguments; the court has not ruled. https://storage.courtlistener.com/recap/gov.uscourts.txed.248221/gov.uscourts.txed.248221.12.0.pdf. Checked October 27, 2026.
  8. Eli Lilly and Company v. Striker Pharmacy, LLC, No. 4:26-cv-06563 (S.D. Tex., filed Aug 12, 2026). Docket: https://www.courtlistener.com/docket/74518163/. Complaint (ECF 1), Lilly’s allegations: Striker “is a compounding pharmacy in Katy, Texas” that “sells these unapproved products to medical practices, including med spas, and also ships them directly to consumers”; “Retatrutide cannot legally be sold for human use to anyone, anywhere, for any reason.” https://storage.courtlistener.com/recap/gov.uscourts.txsd.2103004/gov.uscourts.txsd.2103004.1.0.pdf. Order, October 20, 2026 (ECF 30): “The response of Defendant Striker Pharmacy, LLC to the Complaint is due to be filed on or before October 30, 2026.” https://storage.courtlistener.com/recap/gov.uscourts.txsd.2103004/gov.uscourts.txsd.2103004.30.0.pdf. Scheduling order (ECF 28): “Discovery to be completed by: August 10, 2027”; “Docket call to be held at 11:30 AM on: November 1, 2027.” https://storage.courtlistener.com/recap/gov.uscourts.txsd.2103004/gov.uscourts.txsd.2103004.28.0.pdf. Checked October 27, 2026.
  9. Eli Lilly and Company v. Texas Peptides Inc., No. 5:26-cv-05146 (W.D. Tex., filed Aug 12, 2026; terminated Oct 15, 2026). Docket: https://www.courtlistener.com/docket/74534297/. Notice of voluntary dismissal with prejudice, dated October 15, 2026 (ECF 11): “To date, Defendant Texas Peptides Inc. has not served an answer or motion for summary judgment.” The notice states no settlement terms. https://storage.courtlistener.com/recap/gov.uscourts.txwd.1172926917/gov.uscourts.txwd.1172926917.11.0.pdf. Checked October 27, 2026.
  10. Eli Lilly and Company v. Lone Star Peptide Co. LLC, No. 4:26-cv-06562 (S.D. Tex., filed Aug 12, 2026). Docket: https://www.courtlistener.com/docket/74513992/. Notice of voluntary dismissal with prejudice, dated October 16, 2026 (ECF 10); no terms stated. https://storage.courtlistener.com/recap/gov.uscourts.txsd.2103003/gov.uscourts.txsd.2103003.10.0.pdf. Checked October 27, 2026.
  11. Eli Lilly & Co v. American Peptides LLC, No. 5:26-cv-04146 (W.D. La., filed Oct 8, 2026). Docket: https://www.courtlistener.com/docket/74935388/. Complaint (ECF 1) pleads eight causes of action under the unfair-trade or consumer-protection laws of Alaska, Colorado, Connecticut, North Carolina, South Carolina, Tennessee and Washington and Texas common law, and seeks damages “including disgorgement of profits.” https://storage.courtlistener.com/recap/gov.uscourts.lawd.223926/gov.uscourts.lawd.223926.1.0.pdf. Checked October 27, 2026.
  12. Eli Lilly and Company v. [individual defendant doing business as LiveWell Peptides], No. 3:26-cv-03514 (N.D. Tex., filed Oct 8, 2026). Docket: https://www.courtlistener.com/docket/74935394/. The individual is not named on this page. Checked October 27, 2026.
  13. Eli Lilly and Company v. Cenexa Labs LLC, No. 4:26-cv-08806 (S.D. Tex., filed Oct 8, 2026). Docket: https://www.courtlistener.com/docket/74935400/. Checked October 27, 2026.
  14. Eli Lilly and Company v. Southlake Mhya PLLC (d/b/a Medrein Health & Aesthetics), No. 4:26-cv-01294 (N.D. Tex., filed Oct 8, 2026). Docket: https://www.courtlistener.com/docket/74935411/. Complaint (ECF 1), Lilly’s allegations: the defendant “is a Southlake “med spa””; cause of action “False or Misleading Advertising in Violation of 15 U.S.C. § 1125(a)(1)(B)” (Lanham Act); Lilly asks for an injunction and “An Order requiring Medrein to undertake corrective advertising.” The complaint states: “Neither the U.S. Food and Drug Administration (“FDA”) nor any other regulatory agency in the world has approved a medicine containing retatrutide for any use.” https://storage.courtlistener.com/recap/gov.uscourts.txnd.428373/gov.uscourts.txnd.428373.1.0.pdf. Checked October 27, 2026.
  15. Eli Lilly and Company v. MedShape Weight Loss Clinic LLC, No. 2:26-cv-07361 (D. Ariz., filed Oct 8, 2026). Docket: https://www.courtlistener.com/docket/74940371/. Complaint (ECF 1) pleads false advertising under the Lanham Act and asks the court to bar the clinic from “representing or implying” that retatrutide is FDA-approved. https://storage.courtlistener.com/recap/gov.uscourts.azd.1523789/gov.uscourts.azd.1523789.1.0.pdf. Checked October 27, 2026.
  16. Federal Rule of Civil Procedure 41(a)(1)(A)(i), Legal Information Institute, Cornell Law School: a plaintiff may dismiss an action without a court order by filing a notice “before the opposing party serves either an answer or a motion for summary judgment.” A dismissal “with prejudice” means the same claim cannot be refiled. https://www.law.cornell.edu/rules/frcp/rule_41. Checked October 27, 2026.
  17. U.S. Food and Drug Administration, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (content current as of October 1, 2026): “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.” FDA says it warned “Telehealth companies for marketing unapproved drugs such as retatrutide, including instances of direct marketing to consumers.” https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Checked October 27, 2026.
  18. Victoria Department of Health (Australia), health alert, “Toxicity linked to unapproved peptide product labelled Retatrutide,” issued June 19, 2026 (Chief Health Officer Dr Caroline McElnay): “Since January 2026, there have been six cases of acute liver injury in Victoria in people who have used an unapproved peptide product, labelled as Retatrutide.” “These toxic effects are possibly associated with a contaminant in the products labelled as ‘Retatrutide’ and all such products are at risk.” https://www.health.vic.gov.au/health-alerts/toxicity-linked-to-unapproved-peptide-retatrutide. Checked October 27, 2026.
  19. CBS News, Daniel Gilbert, “Two deaths were reported to the FDA. Is the bootleg weight-loss drug “Reta” to blame?”, updated October 13, 2026, 1:38 PM ET: “The reports link the deaths to products claiming to be retatrutide, though the details aren’t verified and it is unclear whether the drug was to blame”; “Though the reports alone don’t prove that the drugs caused or contributed to patient deaths”; America’s Poison Centers “logged 862 exposures to retatrutide in the three months ending in September, up from 460 in the three months prior and 249 in the first three months of 2026.” https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/. Checked October 27, 2026.
  20. Jabbit source extract for this page: 11 case records (court, number, filing date, status, CourtListener docket), 63 quotes checked against cached copies of the filings and articles on October 27, 2026. https://jabbitapp.com/research/sources/lilly-retatrutide-seller-lawsuits-2026-10-27.json. Checked October 27, 2026.

This page summarizes public court records, company and government statements, and news reports. Statements in complaints and motions are the parties’ allegations and arguments, not findings. It is not legal or medical advice and does not recommend any product, seller or dose. Charts were rebuilt by Jabbit from the sources cited in each caption.